在早期和晚期阿尔茨海默病中,结构网络效率的变化
Suyeon Heo1, Cindy W Yoon2, Sang-Young Kim3,4
1Gachon University, College of Medicine, Incheon, Korea.
Journal of clinical neurology (Seoul, Korea)
|February 8, 2024
概括
早期发病的阿尔茨海默氏症 (EOAD) 显著损害大脑网络的效率和认知能力,与晚期发病的阿尔茨海默氏症 (LOAD) 不同. 负荷,而不是粉样蛋白,与EOAD和LOAD患者的网络变化相关.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 网络科学 网络科学
背景情况:
- 阿尔茨海默病 (AD) 有早期 (EOAD) 和晚期 (LOAD) 的形式.
- 无论是EOAD还是LOAD,都共享粉样蛋白和神经纤维状,但表现出不同的认知特征.
- EOAD和LOAD之间的结构性大脑连接差异仍未得到充分研究.
研究的目的:
- 在EOAD与LOAD患者中使用网络效率来比较结构性大脑连接.
- 评估结构性网络效率和AD的认知功能之间的关联.
- 在AD中调查网络效率和病理标记 (粉样蛋白,) 之间的相关性.
主要方法:
- 扩散张力成像 (DTI) 用于重建80名阿尔茨海默病患者 (47名EOAD,33名LOAD) 和57名对照者的结构性大脑网络.
- 计算用于评估网络效率,路径长度和集群的图形理论指数.
- 分析了网络参数,认知测试结果和粉样蛋白/蛋白负担之间的相关性.
主要成果:
- 与对照组相比,EOAD患者的整体效率降低,路径长度增加,局部效率/聚类降低.
- 与对照组相比,LOAD患者没有表现出明显的全球网络差异.
- 网络变化与EOAD中的认知领域相关,LOAD中的CDR-SB相关.
- 陶负担与AD特征区域的网络变化相关;粉样蛋白负担没有.
结论:
- 结构性网络效率下降及其认知影响在EOAD和LOAD之间存在显著差异.
- 研究结果表明,EOAD与LOAD之间存在不同的神经病理机制或进展.
- 网络分析为AD亚型的不同认知和病理特征提供了洞察力.
更多相关视频
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.2K
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.0K
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
